Trial Profile
An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX Alone for Second-line Treatment of Patients With Metastatic Colorectal Cancer (VOXEL-Study).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Capecitabine; Oxaliplatin
- Indications Colorectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms VOXEL
- 16 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Sep 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 21 Aug 2009 Planned end date changed from 1 Nov 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.